Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America
Abstract Introduction Chronic spontaneous urticaria (CSU) is a disease with a high impact on the quality of life of patients. There are some evaluations of the economic cost of the disease in developed countries, but there is little information about the economic cost of the disease in developing co...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Allergy |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/clt2.70016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582949224054784 |
|---|---|
| author | Jorge Sánchez Leidy Álvarez José Ignacio Larco Luis Ensina Guillermo Guidos‐Fogelbach Cesar A. Reyes‐López German D. Ramon Karla Robles‐Velasco Ivan Cherrez‐Ojeda |
| author_facet | Jorge Sánchez Leidy Álvarez José Ignacio Larco Luis Ensina Guillermo Guidos‐Fogelbach Cesar A. Reyes‐López German D. Ramon Karla Robles‐Velasco Ivan Cherrez‐Ojeda |
| author_sort | Jorge Sánchez |
| collection | DOAJ |
| description | Abstract Introduction Chronic spontaneous urticaria (CSU) is a disease with a high impact on the quality of life of patients. There are some evaluations of the economic cost of the disease in developed countries, but there is little information about the economic cost of the disease in developing countries. Our aim was to assess the economic diagnostic and therapeutic expenses of CSU in five Latin American (LA) countries. Methods A noninterventional multicenter cross‐sectional study was conducted in five LA countries: Brazil, Colombia, Ecuador, Mexico, and Peru. To determine the frequency of medical interventions as well as clinical and sociodemographic characteristics of CSU patients, questionnaires were administered to patients, primary care physicians, allergists, and dermatologists. In each country, diagnostics and therapeutic expenses were calculated by reviewing medical records, health insurance, and interviews. The main outcome was the yearly economic burden from the healthcare insurance perspective in each country. Results According to the projected costs, Brazil had the highest urticaria cost per patient/year (7009.4 USD), followed by Mexico (3695.1 USD), Ecuador (3132.8 USD), Peru (2693.9 USD), and Colombia (2392.8 USD); the cost and the frequency of use of omalizumab and antihistamines explain the total cost differences between countries. Interventions such as medical visits and exams had similar costs between countries and represented less than 10% of total urticaria cost analysis in the five countries. Conclusion The cost of the CSU in LA varies widely based on the health insurance coverage, the cost of the therapies, and the frequency of therapies used. Strengthening national health systems, as well as following the recommendations of international guidelines, seems to reduce the cost of CSU and improve the quality of patients. |
| format | Article |
| id | doaj-art-5eb842813d384da49bd8d31f74dfe717 |
| institution | Kabale University |
| issn | 2045-7022 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Allergy |
| spelling | doaj-art-5eb842813d384da49bd8d31f74dfe7172025-01-29T05:38:32ZengWileyClinical and Translational Allergy2045-70222025-01-01151n/an/a10.1002/clt2.70016Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin AmericaJorge Sánchez0Leidy Álvarez1José Ignacio Larco2Luis Ensina3Guillermo Guidos‐Fogelbach4Cesar A. Reyes‐López5German D. Ramon6Karla Robles‐Velasco7Ivan Cherrez‐Ojeda8Group of Clinical and Experimental Allergy (GACE) Hospital “Alma Mater de Antioquia” University of Antioquia Medellín ColombiaGroup of Clinical and Experimental Allergy (GACE) Hospital “Alma Mater de Antioquia” University of Antioquia Medellín ColombiaAllergy Department “San Felipe” Clinic Lima PeruFederal University of São Paulo São Paulo BrazilResearch at Instituto Politécnico Nacional SEPI/ENMH México City MexicoLaboratorio de Bioquímica Estructural Instituto Politécnico Nacional Escuela Nacional de Medicina y Homeopatía Mexico City MexicoInstituto de Alergia e Inmunologia del Sur Bahia Blanca ArgentinaInstitute for Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin GermanyInstitute for Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin GermanyAbstract Introduction Chronic spontaneous urticaria (CSU) is a disease with a high impact on the quality of life of patients. There are some evaluations of the economic cost of the disease in developed countries, but there is little information about the economic cost of the disease in developing countries. Our aim was to assess the economic diagnostic and therapeutic expenses of CSU in five Latin American (LA) countries. Methods A noninterventional multicenter cross‐sectional study was conducted in five LA countries: Brazil, Colombia, Ecuador, Mexico, and Peru. To determine the frequency of medical interventions as well as clinical and sociodemographic characteristics of CSU patients, questionnaires were administered to patients, primary care physicians, allergists, and dermatologists. In each country, diagnostics and therapeutic expenses were calculated by reviewing medical records, health insurance, and interviews. The main outcome was the yearly economic burden from the healthcare insurance perspective in each country. Results According to the projected costs, Brazil had the highest urticaria cost per patient/year (7009.4 USD), followed by Mexico (3695.1 USD), Ecuador (3132.8 USD), Peru (2693.9 USD), and Colombia (2392.8 USD); the cost and the frequency of use of omalizumab and antihistamines explain the total cost differences between countries. Interventions such as medical visits and exams had similar costs between countries and represented less than 10% of total urticaria cost analysis in the five countries. Conclusion The cost of the CSU in LA varies widely based on the health insurance coverage, the cost of the therapies, and the frequency of therapies used. Strengthening national health systems, as well as following the recommendations of international guidelines, seems to reduce the cost of CSU and improve the quality of patients.https://doi.org/10.1002/clt2.70016chronic spontaneous urticariacost of illnessdiagnostic expensesLatin Americatherapeutic expenses |
| spellingShingle | Jorge Sánchez Leidy Álvarez José Ignacio Larco Luis Ensina Guillermo Guidos‐Fogelbach Cesar A. Reyes‐López German D. Ramon Karla Robles‐Velasco Ivan Cherrez‐Ojeda Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America Clinical and Translational Allergy chronic spontaneous urticaria cost of illness diagnostic expenses Latin America therapeutic expenses |
| title | Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America |
| title_full | Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America |
| title_fullStr | Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America |
| title_full_unstemmed | Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America |
| title_short | Cost‐of‐illness analysis of chronic urticaria clinical management in five countries of Latin America |
| title_sort | cost of illness analysis of chronic urticaria clinical management in five countries of latin america |
| topic | chronic spontaneous urticaria cost of illness diagnostic expenses Latin America therapeutic expenses |
| url | https://doi.org/10.1002/clt2.70016 |
| work_keys_str_mv | AT jorgesanchez costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT leidyalvarez costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT joseignaciolarco costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT luisensina costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT guillermoguidosfogelbach costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT cesarareyeslopez costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT germandramon costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT karlaroblesvelasco costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica AT ivancherrezojeda costofillnessanalysisofchronicurticariaclinicalmanagementinfivecountriesoflatinamerica |